Publications

2024

Morgado B, Klafki HW, Bauer C, Waniek K, Esselmann H, Wirths O, Hansen N, Lachmann I, Osterloh D, Schuchhardt J, Wiltfang J. Assessment of immunoprecipitation with subsequent immunoassays for the blood-based diagnosis of Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci. 2024 Feb 6. doi: 10.1007/s00406-023-01751-2. Epub ahead of print. PMID: 38316685.


Calderón-Garcidueñas L, Stommel EW, Torres-Jardón R, Hernández-Luna J, Aiello-Mora M, González-Maciel A, Reynoso-Robles R, Pérez-Guillé B, Silva-Pereyra HG, Tehuacanero-Cuapa S, Rodríguez-Gómez A, Lachmann I, Galaz-Montoya C, Doty RL, Roy A, Mukherjee PS. Alzheimer and Parkinson diseases, frontotemporal lobar degeneration and amyotrophic lateral sclerosis overlapping neuropathology start in the first two decades of life in pollution exposed urbanites and brain ultrafine particulate matter and industrial nanoparticles, including Fe, Ti, Al, V, Ni, Hg, Co, Cu, Zn, Ag, Pt, Ce, La, Pr and W are key players. Metropolitan Mexico City health crisis is in progress. Front Hum Neurosci. 2024 Jan 12;17:1297467. doi: 10.3389/fnhum.2023.1297467. PMID: 38283093; PMCID: PMC10811680.


2023

Lerche S, Zimmermann M, Roeben B, Wurster I, Fries FL, Deuschle C, Waniek K, Lachmann I, Jakobi M, Joos TO, Knorpp T, Schneiderhan-Marra N, Brockmann K. Inflammatory CSF profiles and longitudinal development of cognitive decline in sporadic and GBA-associated PD. NPJ Parkinsons Dis. 9, 38 (2023). doi: 10.1038/s41531-023-00476-2


2022

Calderón-Garcidueñas L, Stommel EW, Lachmann I, Waniek K, Chao CK, González-Maciel A, García-Rojas E, Torres-Jardón R, Delgado-Chávez R, Mukherjee PS. TDP-43 CSF Concentrations Increase Exponentially with Age in Metropolitan Mexico City Young Urbanites Highly Exposed to PM2.5 and Ultrafine Particles and Historically Showing Alzheimer and Parkinson's Hallmarks. Brain TDP-43 Pathology in MMC Residents Is Associated with High Cisternal CSF TDP-43 Concentrations.  Toxics. 2022 Sep 24;10(10):559. doi: 10.3390/toxics10100559.


Wurster I, Quadalti C, Rossi M, Hauser AK, Deuschle C, Schulte C, Waniek K, Lachmann I, la Fougere C, Doppler K, Gasser T, Bender B, Parchi P, Brockmann K. Linking the phenotype of SNCA Triplication with PET-MRI imaging pattern and alpha-synuclein CSF seeding. NPJ Parkinsons Dis. 2022 Sep 15;8(1):117. doi: 10.1038/s41531-022-00379-8.


Klafki HW, Vogelgsang J, Manuilova E, Bauer C, Jethwa A, Esselmann H, Jahn-Brodmann A, Osterloh D, Lachmann I, Breitling B, Rauter C, Hansen N, Bouter C, Palme S, Schuchhardt J, Wiltfang J. Diagnostic performance of automated plasma amyloid-β assays combined with pre-analytical immunoprecipitation.  Alzheimers Res Ther. 2022 Sep 7;14(1):127. doi: 10.1186/s13195-022-01071-y.


Lerche S, Zimmermann M, Wurster I, Roeben B, Fries FL, Deuschle C, Waniek K, Lachmann I, Gasser T, Jakobi M, Joos TO, Schneiderhan-Marra N, Brockmann K. CSF and Serum Levels of Inflammatory Markers in PD: Sparse Correlation, Sex Differences and Association With Neurodegenerative Biomarkers.  Front Neurol. 2022 Feb 25;13:834580. doi:10.3389/fneur.2022.834580


2021

Lerche S, Sjödin S, Brinkmalm A, Blennow K, Wurster I, Roeben B, Zimmermann M, Hauser AK, Liepelt-Scarfone I, Waniek K,Lachmann I, Gasser T, Zetterberg H, Brockmann K. CSF Protein Level of Neurotransmitter Secretion, Synaptic Plasticity, and Autophagy in PD and DLB. Mov Disord. 2021 Nov;36(11):2595-2604. doi: 10.1002/mds.28704.


Brockmann K, Quadalti C, Lerche S, Rossi M, Wurster I, Baiardi S, Roeben B, Mammana A, Zimmermann M, Hauser AK, Deuschle C, Schulte C, Waniek K,Lachmann I, Sjödin S, Brinkmalm A, Blennow K, Zetterberg H, Gasser T, Parchi P. Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson's disease and dementia with Lewy bodies. Acta Neuropathol Commun. 2021 Oct 30;9(1):175. doi: 10.1186/s40478-021-01276-6


Stelzl E, Ciesek S, Cornberg M, Maasoumy B, Heim A, Chudy M, Olivero A, Miklau FN, Nickel A, ReinhardtA, Dietzsch M, Kessler HH. Reliable quantification of plasma HDV RNA is of paramount importance for treatment monitoring: A European multicenter study. J Clin Virol. 2021 Sep;142:104932. doi: 10.1016/j.jcv.2021.104932. Epub 2021 Jul 24. PMID: 34333392


Lerche S, Schulte C, Wurster I, Machetanz G, Roeben B, Zimmermann M, Deuschle C, Hauser AK, Böhringer J, Krägeloh-Mann I, Waniek K, Lachmann I, Petterson XT, Chiang R, Park H, Wang B, Liepelt-Scarfone I, Maetzler W, Galasko D, Scherzer CR, Gasser T, Mielke MM, Hutten SJ, Mollenhauer B, Sardi SP, Berg D, Brockmann K. The Mutation Matters: CSF Profiles of GCase, Sphingolipids, α-Synuclein in PDGBA. Mov Disord. 2021 Feb 6. doi: 10.1002/mds.28472


2020

Calderón-Garcidueñas L, González-Maciel A, Reynoso-Robles R, Hammond J, Kulesza R, Lachmann I, Torres-Jardón R, Mukherjee PS, Maher BA. Quadruple abnormal protein aggregates in brainstem pathology and exogenous metal-rich magnetic nanoparticles (and engineered Ti-rich nanorods). The substantia nigrae is a very early target in young urbanites and the gastrointestinal tract a key brainstem portal. Environ Res. 2020 Dec;191:110139. doi: 10.1016/j.envres.2020.110139. Epub 2020 Sep 2. PMID: 32888951


Klafki HW, Rieper P, Matzen A, Zampar S, Wirths O, Vogelgsang J, Osterloh D, Rohdenburg L, Oberstein TJ, Jahn O, Beyer I, Lachmann I, Knölker HJ, Wiltfang J. Development and Technical Validation of an Immunoassay for the Detection of APP669-711 (Aβ-3-40) in Biological Samples. Int J Mol Sci. 2020 Sep 8;21(18):6564. doi: 10.3390/ijms21186564. PMID: 32911706


Bousiges O, Philippi N, Lavaux T, Perret-Liaudet A, Lachmann I, Schaeffer-Agalède C, Anthony P, Botzung A, Rauch L, Jung B, de Sousa PL, Demuynck C, Martin-Hunyadi C, Cretin B, Blanc F. Differential diagnostic value of total alpha-synuclein assay in the cerebrospinal fluid between Alzheimer's disease and dementia with Lewy bodies from the prodromal stage.  Alzheimers Res Ther. 2020 Sep 29;12(1):120. doi: 10.1186/s13195-020-00684-5. PMID: 32993772


Schmidt S, Stapf C, Schmutzler S, Lachmann I, Arendt T, Holzer M, Sonntag M, Morawski M. Aggrecan modulates the expression and phosphorylation of tau in a novel bigenic TauP301L - acan mouse model. Eur J Neurosci. 2020 Aug 1. doi:10.1111/ejn.14923. Epub ahead of print. PMID: 32737917


Vallabh SM, Minikel EV, Williams VJ, Carlyle BC, McManus AJ, Wennick CD, Bolling A, Trombetta BA, Urick D, Nobuhara CK, Gerber J, Duddy H, Lachmann I, Stehmann C, Collins SJ, Blennow K, Zetterberg H, Arnold SE. Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease. BMC Med. 2020 Jun 18;18(1):140. doi: 10.1186/s12916-020-01608-8. PMID: 32552681; PMCID: PMC7302371


Llorens F, Villar-Piqué A, Hermann P, Schmitz M, Goebel S, Waniek K, Lachmann I, Zerr I. Cerebrospinal fluid non-phosphorylated tau in the differential diagnosis of Creutzfeldt-Jakob disease: a comparative prospective study with 14-3-3. J Neurol. 2020 Feb;267(2):543-550. doi: 10.1007/s00415-019-09610-8. Epub 2019 Nov 7. PMID: 31701333


Lerche S, Wurster I, Roeben B, Zimmermann M, Riebenbauer B, Deuschle C, Hauser AK, Schulte C, Berg D, Maetzler W, Waniek K, Lachmann I, Liepelt-Scarfone I, Gasser T, Brockmann K. Parkinson's Disease: Glucocerebrosidase 1 Mutation Severity Is Associated with CSF Alpha-Synuclein Profiles. Mov Disord. 2020 Mar;35(3):495-499. doi: 10.1002/mds.27884


Wurster I, Lerche S, Hauser AK, Schulte C, Lachmann I, Beschorner R, Neumann M, Brockmann K. Do longitudinal cerebrospinal fluid profiles correspond to postmortem brain pathology in LRRK2 Parkinson's disease? Eur J Neurol. 2020 Jan;27(1):e5-e6. doi: 10.1111/ene.14060


2019

Lerche S, Machetanz G, Wurster I, Roeben B, Zimmermann M, Pilotto A, Preische O, Stransky E, Deuschle C, Hauser AK, Schulte C, Lachmann I, Waniek K, Gasser T, Berg D, Maetzler W, Brockmann K. Dementia with lewy bodies: GBA1 mutations are associated with cerebrospinal fluid alpha-synuclein profile. Mov Disord. 2019 Jul;34(7):1069-1073. doi: 10.1002/mds.27731


Villar-Piqué A, Schmitz M, Lachmann I, Karch A, Calero O, Stehmann C, Sarros S, Ladogana A, Poleggi A, Santana I, Ferrer I, Mitrova E, Žáková D, Pocchiari M, Baldeiras I, Calero M, Collins SJ, Geschwind MD, Sánchez-Valle R, Zerr I, Llorens F. Cerebrospinal Fluid Total Prion Protein in the Spectrum of Prion Diseases. Mol Neurobiol. 2019 Apr;56(4):2811-2821. doi: 10.1007/s12035-018-1251-1. Epub 2018 Jul 30. PMID: 30062673


Santos JRF, Bauer C, Schuchhardt J, Wedekind D, Waniek K, Lachmann I, Wiltfang J, Vogelgsang J. Validation of a prototype tau Thr231 phosphorylation CSF ELISA as a potential biomarker for Alzheimer's disease. J Neural Transm (Vienna). 2019 Mar;126(3):339-348. doi: 10.1007/s00702-019-01982-5


Fourier A, Escal J, Bernard E, Lachman I, Perret-Liaudet A, Leblanc P, Quadrio I. Development of an automated capillary nano-immunoassay-Simple Western assay-to quantify total TDP43 protein in human platelet samples. Anal Bioanal Chem. 2019 Jan;411(1):267-275. doi: 10.1007/s00216-018-1437-4


2018

Calderón-Garcidueñas L, Mukherjee PS, Waniek K, Holzer M, Chao CK, Thompson C, Ruiz-Ramos R, Calderón-Garcidueñas A, Franco-Lira M, Reynoso-Robles R, Gónzalez-Maciel A, Lachmann I. Non-Phosphorylated Tau in Cerebrospinal Fluid is a Marker of Alzheimer's Disease Continuum in Young Urbanites Exposed to Air Pollution. J Alzheimers Dis. 2018;66(4):1437-1451. doi: 10.3233/JAD-180853


Dos Santos MCT, Scheller D, Schulte C, Mesa IR, Colman P, Bujac SR, Bell R, Berteau C, Perez LT, Lachmann I, Berg D, Maetzler W, Nogueira da Costa A. Evaluation of cerebrospinal fluid proteins as potential biomarkers for early stage Parkinson's disease diagnosis. PLoS One. 2018 Nov 1;13(11): e0206536. doi: 10.1371/journal.pone.0206536


Llorens F, Barrio T, Correia Â, Villar-Piqué A, Thüne K, Lange P, Badiola JJ, Schmitz M, Lachmann I, Bolea R, Zerr I. Cerebrospinal Fluid Prion Disease Biomarkers in Pre-clinical and Clinical Naturally Occurring Scrapie. Mol Neurobiol. 2018 Nov;55(11):8586-8591. doi: 10.1007/s12035-018-1014-z. Epub 2018 Mar 23. PMID: 29572672.


2017

Lerche S, Schulte C, Srulijes K, Pilotto A, Rattay TW, Hauser AK, Stransky E, Deuschle C, Csoti I, Lachmann I, Zetterberg H, Liepelt-Scarfone I, Gasser T, Maetzler W, Berg D, Brockmann K. Cognitive impairment in Glucocerebrosidase (GBA)-associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles. Mov Disord. 2017 Dec;32(12):1780-1783. doi: 10.1002/mds.27199


Nuvolone M, Schmid N, Miele G, Sorce S, Moos R, Schori C, Beerli RR, Bauer M, Saudan P, Dietmeier K, Lachmann I, Linnebank M, Martin R, Kallweit U, Kana V, Rushing EJ, Budka H, Aguzzi A. Cystatin F is a biomarker of prion pathogenesis in mice. PLoS One. 2017 Feb 8;12(2)


Lewczuk P, Lelental N, Lachmann I, Holzer M, Flach K, Brandner S, Engelborghs S, Teunissen CE, Zetterberg H, Molinuevo JL, Mroczko B, Blennow K, Popp J, Parnetti L, Chiasserini D, Perret-Liaudet A, Spitzer P, Maler JM, Kornhuber J. Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization. J Alzheimers Dis. 2017;55(1):159-170


2016

Calderón-Garcidueñas L, Avila-Ramírez J, Calderón-Garcidueñas A, González-Heredia T, Acuña-Ayala H, Chao CK, Thompson C, Ruiz-Ramos R, Cortés-González V, Martínez-Martínez L, García-Pérez MA, Reis J, Mukherjee PS, Torres-Jardón R, Lachmann I. Cerebrospinal Fluid Biomarkers in Highly Exposed PM2.5 Urbanites: The Risk of Alzheimer's and Parkinson's Diseases in Young Mexico City Residents. J Alzheimers Dis. 2016 Sep 6;54(2):597-613


Fröhlich C, Zschiebsch K, Gröger V, Paarmann K, Steffen J, Thurm C, Schropp EM, Brüning T, Gellerich F, Radloff M, Schwabe R, Lachmann I, Krohn M, Ibrahim S, Pahnke J. Activation of Mitochondrial Complex II-Dependent Respiration Is Beneficial for α-Synucleinopathies. Mol Neurobiol. 2016 Sep;53(7):4728-44


2015

Herrmann L, Wiegmann C, Arsalan-Werner A, Hilbrich I, Jäger C, Flach K, Suttkus A, Lachmann I, Arendt T, Holzer M. Hook proteins: association with Alzheimer pathology and regulatory role of hook3 in amyloid beta generation. PLoS One. 2015


Bétemps D, Verchère J, Mougenot AL, Lachmann I, Morignat E, Antier E, Lakhdar L, Legastelois S, Baron T. Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein. J Vis Exp. 2015


Zschiebsch K, Gröger V, Paarmann K, Steffen J, Thurm C, Schropp EM, Brüning T, Gellerich F, Radloff M, Schwabe R, Lachmann I, Krohn M, Ibrahim S, Pahnke J. Activation of Mitochondrial Complex II-Dependent Respiration Is Beneficial for α-Synucleinopathies. Mol Neurobiol. 2015


2014

Dorey A, Tholance Y, Vighetto A, Perret-Liaudet A, Lachman I, Krolak-Salmon P, Wagner U, Struyfs H, De Deyn PP, El-Moualij B, Zorzi W, Meyronet D, Streichenberger N, Engelborghs S, Kovacs GG, Quadrio I. Association of cerebrospinal fluid prion protein levels and the distinction between Alzheimer disease and Creutzfeldt-Jakob disease. JAMA Neurol. 2015 Mar;72(3):267-75. doi: 10.1001/jamaneurol.2014.4068


Flach K, Ramminger E, Hilbrich I, Arsalan-Werner A, Albrecht F, Herrmann L, Goedert M, Arendt T, Holzer M. Axotrophin/MARCH7 acts as an E3 ubiquitin ligase and ubiquitinates tau protein in vitro impairing microtubule binding. Biochim Biophys Acta. 2014 Sep;1842(9):1527-38. doi: 10.1016/j.bbadis.2014.05.029


Unterberger U, Lachmann I, Voigtländer T, Pirker W, Berghoff AS, Flach K, Wagner U,Geneste A, Perret-Liaudet A, Kovacs GG. Detection of disease-associated α-synuclein in the cerebrospinal fluid: a feasibility study. Clin Neuropathol. 2014 Sep-Oct;33(5):329-34


Kovacs GG, Breydo L, Green R, Kis V, Puska G, Lőrincz P, Perju-Dumbrava L, Giera R, Pirker W, Lutz M, Lachmann I, Budka H, Uversky VN, Molnár K, László L. Intracellular processing of disease-associated α-synuclein in the human brain suggests prion-like cell-to-cell spread. Neurobiol Dis. 2014 Sep;69:76-92


Wolf J, Jäger C, Morawski M, Lachmann I, Schönknecht P, Mothes T, Arendt T. Tissue transglutaminase in Alzheimer's disease - facts and fiction: a reply to "Tissue transglutaminase is a biochemical marker for Alzheimer's disease". Neurobiol Aging. 2014 Apr;35(4):e5-9


2013

Wolf J, Jäger C, Lachmann I, Schönknecht P, Morawski M, Arendt T, Mothes T. Tissue transglutaminase is not a biochemical marker for Alzheimer's disease. Neurobiol Aging. 2013 Nov;34(11):2495-8


2012

Flach K, Hilbrich I, Schiffmann A, Gärtner U, Krüger M, Leonhardt M, Waschipky H, Wick L, Arendt T, Holzer M. Tau oligomers impair artificial membrane integrity and cellular viability. J Biol Chem. 2012 Dec 21;287(52):43223-33. doi: 10.1074/jbc.M112.396176


Kovacs GG, Wagner U, Dumont B, Pikkarainen M, Osman AA, Streichenberger N, Leisser I, Verchère J, Baron T, Alafuzoff I, Budka H, Perret-Liaudet A, Lachmann I. An antibody with high reactivity for disease-associated α-synuclein reveals extensive brain pathology. Acta Neuropathol. 2012 Jul;124(1):37-50


2011

Wolf J, Lachmann I, Wagner U, Osman AA, Mothes T. Quantification of human tissue transglutaminase by a luminescence sandwich enzyme-linked immunosorbent assay. Anal Biochem. 2011 Dec 15;419(2):153-60


Wolf J, Lachmann I, Wagner U, Osman AA, Mothes T. Immunoassay of in vitro activated human tissue transglutaminase. Anal Biochem. 2011 Apr 1;411(1):10-5